ARCHIVES

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

This article is from The Cancer Letter archive.

Vol. 02 No. 37 | September 10, 1976

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays Consideration Of New New Heavy Particle Therapy Studies

March 8, 1985

ESA Risk Mitigation Strategy Requires Training, Patient Consent, Documentation

February 19, 2010

MIT Radiation Poisoning Was Deliberate, NRC Investigation Finds

December 15, 1995

New Mexico, Michigan Win Saturation Implementation Contracts

June 6, 1975

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

May 21, 2004

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

January 31, 2014